Rex Ahmed, listed on the Tokyo Stock Exchange Mothers drug development = February 13 (initial public offering)

February 13, drex <4586> (Higashikagawa Kagawa, Makoto Matsumura good president) is listed on the Tokyo Stock Exchange Mothers. Development of drugs that use proprietary transdermal technology. Has produced an adhesive patch or ointment, such as bed sores and pain relief, skin ulcers. Clinical trials and other research and development expenses, financing of approximately 1.6 billion yen, to finance the operation.
According to the president Matsumura, compared to oral administration, without being "first pass effect" it from being the absorbing component, such as organs other than the affected area, a relatively small amount of medication, drug transdermal is difficult to produce side effects. In addition, there is an advantage to be easy to maintain the effect, such as the elderly is likely to swallow also difficult patient.
The company has dramatically improved the permeability of the component that the melting point of the ionic conductivity to use the "ionic liquid" high-low, in the prior art cause the absorption through the skin is difficult.
In addition, we are aiming to sell in the United States "ETOREAT" is anti-inflammatory analgesic patch was the first to take advantage of the technology. The adhesive patch, and some thick poultice, agents are non-hydrous hydrous thin tape. Japan said the tape agent has increased its share of anti-inflammatory analgesics as ease of use, in the United States is that it is still common poultice, expansion in the U.S. market is expected.